+

WO1993021179A1 - Nouvelle piperazine d'aminoalkyle et d'iminoalkyle - Google Patents

Nouvelle piperazine d'aminoalkyle et d'iminoalkyle Download PDF

Info

Publication number
WO1993021179A1
WO1993021179A1 PCT/SE1993/000295 SE9300295W WO9321179A1 WO 1993021179 A1 WO1993021179 A1 WO 1993021179A1 SE 9300295 W SE9300295 W SE 9300295W WO 9321179 A1 WO9321179 A1 WO 9321179A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
compound
hydrogen atom
general formula
carbon atoms
Prior art date
Application number
PCT/SE1993/000295
Other languages
English (en)
Inventor
Stefan Bengtsson
Lennart Florvall
Gerd Hallnemo
David Jackson
Svante Ross
Bo-Ragnar Tolf
Bengt Ulff
Lian Zhang
Christina ÅKESSON
Original Assignee
Aktiebolaget Astra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aktiebolaget Astra filed Critical Aktiebolaget Astra
Priority to CZ932701A priority Critical patent/CZ270193A3/cs
Priority to EP93909109A priority patent/EP0594813A1/fr
Priority to JP5518225A priority patent/JPH06508378A/ja
Priority to AU39643/93A priority patent/AU665825B2/en
Priority to SK1389-93A priority patent/SK138993A3/sk
Publication of WO1993021179A1 publication Critical patent/WO1993021179A1/fr
Priority to NO934426D priority patent/NO934426D0/no
Priority to NO934426A priority patent/NO180794C/no
Priority to FI935494A priority patent/FI935494L/fi
Priority to BG98281A priority patent/BG98281A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/62—Naphtho [c] pyrroles; Hydrogenated naphtho [c] pyrroles
    • C07D209/66—Naphtho [c] pyrroles; Hydrogenated naphtho [c] pyrroles with oxygen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Definitions

  • the present invention relates to novel, 1-aryl-4( ⁇ -amido-1-alkyl and ⁇ -imido-1-alkyl)piperazines, intermediates and processes for their preparation, pharmaceutical compositions containing the piperazines and to the use of said compounds in therapy.
  • the object of the present invention is to provide novel compounds that will be useful in the treatment of psychiatric disorders such as schizophrenia and other psychoses, anxiety, depression and manic-depressive psychosis.
  • R is a hydrogen atom or a phenyl group
  • m is an integer 3 to 8
  • R 4 is situated in the meta or para position of the ring and represents an NO 2 -group or a group NR 7 R 8 wherein R 7 and R 8 are the same or different and each represents a hydrogen atom or an alkyl group having 1-3 carbon atoms,
  • R 5 is situated in the ortho, meta or para position and represents a hydrogen atom, a halogen atom, or CF 3 ,
  • R 6 is situated in the ortho, meta or para position and represents a halogen atom or CF 3
  • W is an optionally substituted aromatic ring(s), a heterocyclic ring, a carbocyclic ring(s), or an optionally substituted methylene group
  • A is a hydrogen atom, a hydroxy group, a halogen atom, CF 3 , an alkyl group having 1-3 carbon atoms, an alkoxy group having 1-3 carbon atoms, a phenyl group, or a phenoxy group,
  • B is a hydrogen atom
  • a and B together constitute a carbonyl group, n 1 is 0 or 1, and n 2 is 0 or 1, in racemic or optically active form, or as a mixture of diastereomers, provided that 1) when W is an optionally substituted aromatic ring(s) then
  • R, m, R 4 , R 5 , and Rg are as defined above,
  • n 1 is 0 or 1
  • n 2 is 0 or 1
  • A is a hydrogen atom, a halogen atom, CF 3 , a hydroxy group, an alkyl group having 1-3 carbon atoms, an alkoxy group having 1-3 carbon atoms, a phenyl group, or a phenoxy group, and
  • B is a hydrogen atom
  • R, m, R 4 , R 5 , and R 6 are as defined above,
  • n 1 is 0 or 1
  • n 2 is 0 or 1
  • a and B are hydrogen atoms or A and B together constitute a carbonyl group
  • R, m, R 4 , R 5 , and R 6 are as defined above,
  • n 1 and n 2 are 1 or
  • n 1 is 1 and n 2 is 0 or
  • An aromatic ring(s) in the definition above is preferably phenyl or naphthyl and is mono- or disubstituted, wherein the substituents are preferably chosen from the following: a hydrogen atom, a halogen atom, a hydroxy group, CF 3 , an alkyl group (s) having 1-3 carbon atoms, or an alkoxy group (s) having 1-3 carbon atoms.
  • Heterocyclic ring in the definition above is preferably furyl, thienyl, pyrrolyl, pyridyl, or indolyl.
  • a carbocyclic ring(s) in the definition above is preferably mono, bi, or polycyclic rings having 3-12 carbon atoms.
  • the substituents on the carbocyclic ring(s) in the definition above are preferably a hydrogen atom or an alkyl group having 1-3 carbon atoms.
  • the substituent on the methylene group in the definition above is preferably a hydrogen atom or an alkyl group having 1-4 carbon atoms.
  • Halogen in the definition above is preferably a chlorine, bromine, or fluorine atom.
  • R 1 is situated in the 3- or 4-position and represents a hydrogen atom, a halogen atom, CF 3 , an alkyl group having 1-3 carbon atoms, an alkoxy group having 1-3 carbon atoms, NO 2 , COCH 3 , or NR 2 R 3 wherein R 2 and R 3 are the same or different and each represents a hydrogen atom or an alkyl group having 1-6 carbon atoms, m is an integer 3 to 8,
  • R 4 is situated in the meta or para position of the ring and represents an NO 2 group or a group NR 7 R 8 wherein R 7 and R 8 are the same or different and each represents a hydrogen atom or an alkyl group having 1-3 carbon atoms,
  • R 5 is situated in the ortho, meta, or para position of the ring and represents a hydrogen atom, a halogen atom, or CF 3
  • R 6 is situated in the ortho, meta, or para position of the ring and represents a halogen atom or CF 3
  • W is preferably chosen from the following groups : the substituents preferably being a halogen atom, a hydroxy group, or a methoxy group, mcst preferred are bromine, hydroxy, or methoxy in the ortho and/or meta positions.
  • m is preferably 4-6
  • R 4 is preferably NH 2 ,
  • R 4 is NH 2 in the meta or para positions
  • R 5 is preferably hydrogen or halogen
  • R 5 is hydrogen, chlorine, or bromine
  • R 5 are hydrogen or chlorine in the meta or para positions
  • R 6 is preferably CF 3 or halogen
  • R 6 is CF 3 or chlorine
  • R 6 are CF 3 or chlorine in the meta position.
  • R is preferably H.
  • n 1 is preferably 0 and n 2 is preferably 0 or 1, most preferred n 2 is 0,
  • A is preferably hydrogen, methoxy, or hydroxy in the ortho position.
  • n 1 is preferably 0.
  • n 1 is preferably 0,
  • A is preferably a hydrogen atom or an alkyl group with 1- 3 carbon atoms
  • W is viii, then
  • n 1 and n 2 are preferably 0 and
  • a and B preferably constitute a carbonyl group.
  • n 1 and n 2 are preferably 1 and
  • a and B preferably constitute a carbonyl group
  • n 1 and n 2 are preferably 0 and
  • a and B preferably constitute a carbonyl group
  • Both organic and inorganic acids can be employed to form non-toxic pharmaceutically acceptable acid addition salts of the compounds of this invention.
  • Illustrative acids are sulfuric, nitric, phosphoric, oxalic, hydrochloric, formic, hydrobromic, citric, acetic, lactic, tartaric, pamoic, ethanedisulfonic, sulfamic, succinic, propionic, glycollic, malic, mandelic acid, gluconic, pyruvic, phenylacetic, 4-aminobenzoic, anthranilic, salicylic, 4-aminosalicylic, 4-hydroxybenzoic, nicotinic, methanesulfonic, ethanesulfonic, hydroxyethanesulfonic, benzenesulfonic, p-toluenesulfonic, sulfanilic, naphthalenesulfonic, ascorbic, cyclohexyl
  • R is a hydrogen atom or a phenyl group
  • m is an integer 3 to 8
  • R 4 is situated in the meta or para position of the ring and represents an NC 2 -group or a group NR 7 R 8 wherein R 7 and R 8 are the same or different and each represents a hydrogen atom or an alkyl group having 1-3 carbon atoms,
  • R 5 is situated in the ortho, meta or para position and represents a hydrogen atom, a halogen atom, or CF 3 ,
  • R 6 is situated in the ortho, meta or para position and represents a halogen atom, or CF 3 ,
  • W is an optionally substituted aromatic ring(s), a heterocyclic ring, a carbocyclic ring(s), or an optionally substituted methylene group,
  • A is a hydrogen atom, a hydroxy group, a halogen atom, CF 3 , an alkyl group having 1-3 carbon atoms, an alkoxy group having 1-3 carbon atoms, a phenyl group, or a phenoxy group,
  • B is a hydrogen atom, or A and B together constitute a carbonyl group, n 1 is 0 or 1, and n 2 is 0 or 1, in racemic or optically active form, or as a mixture of diastereomers, provided that 1) when W is an optionally substituted aromatic ring(s) then
  • R, m, R 4 , R 5 , and R 6 are as defined above,
  • n 1 is 0 or 1
  • n 2 is 0 or 1
  • A is a hydrogen atom, a halogen atom, CF 3 , a hydroxy group, an alkyl group having 1-3 carbon atoms, an alkoxy group having 1-3 carbon atoms, a phenyl group, or a phenoxy group and
  • B is a hydrogen atom
  • R, m, R 4 , R 5 , and R 6 are as defined above,
  • n 1 is 0 or 1
  • n 2 is 0 or 1
  • a and B are hydrogen atoms or
  • a and B together constitute a carbonyl group, 3) when W is an optionally substituted methylene group then
  • R, m, R 4 , R 5 , and R 6 are as defined above, n 1 and n 2 are 1 or
  • n 1 is 1 and n 2 is 0 or
  • a and B together constitute a carbonyl group are prepared by any of the following alternative methods
  • R, m, W, A, B, n 1 and n 2 are as defined above and X is a suitable leaving group such as halogen, arylsulfonate or alkylsulfonate, with a compound of the general formula III
  • R 4 , R 5 and R 6 are as defined above in a suitable solvent, such as an alcohol, DMF, acetonitrile or DMSO in the presence of a base such as triethylamine, sodium hydroxide, or potassium carbonate and a catalytic amount of a sodium or potassium halide, such as KI at ambient or higher temperature for a prolonged time.
  • a suitable solvent such as an alcohol, DMF, acetonitrile or DMSO
  • a base such as triethylamine, sodium hydroxide, or potassium carbonate
  • a catalytic amount of a sodium or potassium halide such as KI at ambient or higher temperature for a prolonged time.
  • R, m, R 5 , R 6 , W, A, B, n 1 and n 2 are as defined above and Y is situated in the meta or para position and represents a group which can be transformed to a group R 4 , where R 4 is situated in the meta or para position of the ring and represents a group NR 7 R 8 , wherein R 7 and R 8 are as defined above, by a suitable hydrolytic, reductive, electrochemical or other known processes.
  • Compounds of the formula IV can be prepared according to Method A.
  • Such a group Y may be chosen from easily cleaved amides, carbamates, imines, benzylic amines or other suitably protected amino groups.
  • Such groups can be trifluoroacetamido, formamido, t-butoxycarbonylamino, or N-benzylamino .
  • Y can be a group such as nitro, azido, hydroxyamino, hydrazono, amido or imino, which can be transformed to R 4 1 by known reductive processes.
  • R, m, W, A, B, n 1 and n 2 are as defined above and Z is hydrogen, hydroxy, halogen, or alkoxy, with a compound of the general formula III
  • R 4 , R 5 and R 6 are as defined above in the presence of a suitable reducing agent such as sodium cyanoborohydride or lithium aluminium hydride in a direct or stepwise manner.
  • a suitable reducing agent such as sodium cyanoborohydride or lithium aluminium hydride in a direct or stepwise manner.
  • W, n 1 , n 2 , and A are as defined above, and T independently or together with A represents a suitable derivative of an aliphatic, cycloaliphatic, aromatic or heterocyclic acid or acid derivative, such as a halide, an ester, an imide, an anhydride, or other acid activating group, with a compound of the general formula VII
  • m, R 4 , R 5 and R 6 are as defined above, in a suitable solvent such as dichloromethane, chloroform, toluene, acetic acid, or tetrahydrofuran or neat at ambient or elevated temperature for a prolonged time.
  • a suitable solvent such as dichloromethane, chloroform, toluene, acetic acid, or tetrahydrofuran or neat at ambient or elevated temperature for a prolonged time.
  • R, m, R 4 , W, A, B, n 1 and n 2 are as defined above and R 5 is H, halogen, or CF 3 with a suitable halogenating reagent such as sulfuryl chloride, or bromine in a suitable solvent such, as chloroform or dioxane.
  • a suitable halogenating reagent such as sulfuryl chloride, or bromine in a suitable solvent such, as chloroform or dioxane.
  • W, n 1 and n 2 are as defined above, A and B together represent a carbonyl group, and M represents a suitable alkali metal such as sodium or potassium, with a compound of the general formula X
  • X, R 4 , R 5 and R 6 are as defined above in a suitable solvent such as DMF, acetonitrile, or DMSO in the presence of a base such as triethylamine, sodium hydroxide, or potassium carbonate at ambient or higher temperature for a prolonged time.
  • a suitable solvent such as DMF, acetonitrile, or DMSO
  • a base such as triethylamine, sodium hydroxide, or potassium carbonate
  • a compound of the general formula II wherein R, m, W, A, B, n 1 , n 2 and X are as defined above, can be prepared by reacting a compound of the general formula VI
  • W, n 1 , n 2 , and A are as defined above, and T independently or together with A represents a suitable derivative of an aliphatic, cycloaliphatic, aromatic or heterocyclic acid or acid derivative, such as a halide, an ester, an imide, an anhydride, or other acid activating group, with a compound of the general formula XI
  • R, m, W, A, B, n 1 and n 2 are as defined above, with a suitable halogenating agent such as thionyl chloride, phosgene, oxalyl chloride, or phosphorous tribromide, or with a suitable sulfonating agent such as tosyl chloride or other arylsulfonyl chloride or alkylsulfonyl chloride.
  • a suitable halogenating agent such as thionyl chloride, phosgene, oxalyl chloride, or phosphorous tribromide
  • a suitable sulfonating agent such as tosyl chloride or other arylsulfonyl chloride or alkylsulfonyl chloride.
  • R 4 1 , R 5 and R 6 are as defined above can be prepared from a compound of the general formula XIII
  • R 5 and R 6 are as defined above and Y is NO 2 can be prepared by reacting a compound of the general formula XIV
  • R 5 and R 6 are as defined above, Y is NO 2 and U is a halogen, with piperazine or a suitably monosubstituted piperazine, where the substituent is easily removeable, such as a benzyl or an ethoxycarbonyl group,
  • X is as defined above and V is hydrogen or an easily removable group such as benzyl or ethoxycarbonyl.
  • the compounds of the formula I will normally be administered orally, rectally or by injection, in the form of pharmaceutical preparations comprising the active ingredient either as a free base or a pharmaceutically acceptable non-toxic, acid addition salt, e.g. the hydrochloride, hydrobromide, lactate, acetate, phosphate, sulfate, sulfamate, citrate, tartrate, oxalate and the like in association with a pharmaceutically acceptable dosage form.
  • the dosage form may be a solid, semisolid or liquid preparation.
  • the active substance will constitute between 0.1 and 99 % by weight of the preparation, more specifically between 0.5 and 20 % by weight for preparations intended for injection and between 0.2 and 50 % by weight for preparations suitable for oral administration.
  • the selected compound may be mixed with a solid excipient, e.g. lactose, saccharose, sorbitol, mannitol, starches such as potato starch, corn starch or amylopectin, cellulose derivatives, a binder such as gelatine or polyvinylpyrrolidone, and a lubricant such as magnesium stearate, calcium stearate, polyethylene glycol, waxes, paraffin, and the like, and then compressed into tablets.
  • a concentrated sugar solution which may contain, e.g.
  • the tablet can be coated with a polymer well known in the art, dissolved in a readily volatile organic solvent or mixture of organic solvents or in water. Dyestuffs may be added to these coatings in order to readily distinguish between tablets containing different active substances or different amounts of the active compounds.
  • the active substance may be admixed with e.g. a vegetable oil or polyethylene glycol.
  • Hard gelatine capsules may contain granules of the active substance using either the above mentioned excipients for tablets e.g. saccharose, sorbitol, mannitol, starches (e.g. potato starch, corn starch or amylopectin), cellulose derivatives or gelatine. Also liquids or semisolids of the drug can be filled into hard gelatine capsules.
  • Dosage units for rectal application can be solutions or suspensions or can be prepared in the form of suppositories comprising the active substance in admixture with a neutral fatty base, or gelatine rectal capsules comprising the active substance in admixture with vegetable oil or paraffin oil.
  • Liquid preparations for oral application may be in the form of syrups or suspensions, for example, solutions containing from about 0.2 % to about 20 % by weight of the active substance herein described, the balance being sugar and mixture of ethanol, water, glycerol, and propylene glycol.
  • Such liquid preparations may contain colouring agents, flavouring agents, saccharin and carboxymethylcellulose as a thickening agent or other excipients well known in the art .
  • Solutions for parenteral applications can be prepared in an aqueous solution of a water-soluble pharmaceutically acceptable salt of the active substance preferably in a concentration of from about 0.5 % to about 10 % by weight. These solutions may also contain stabilizing agents and/or buffering agents and may conveniently be provided in various dosage unit ampoules .
  • Suitable daily doses of the compounds of the invention in the therapeutic treatment of humans are 50 - 500 mg by oral administration and up to 100 mg via parenteral administration.
  • Example 4 1-(4-Amino-3-trifluoromethylphenyl) -4-[4-(4-chlorophthalimido)-1-butyl]piperazine dihydrochloride.
  • Example 18 1-(4-Amino-3-methylphenyl)-4-(4-phthalimido-1-butyl)-piperazine acetate.
  • Example 13 The product in Example 13 (1.0 g, 2 mmol) was dissolved in 20 ml dioxane and 5 ml methanol. Bromine (350 mg, 2.2 mmol) dissolved in 3 ml dioxane was added and the mixture stirred at ambient temperature for 5 hours, the solvent evaporated, the residue made alkaline with 2 M aqueous NaOH and extracted with methylene chloride. The solvent was removed and the residue dissolved in diisopropyl ether and a precipitate of the title compound was obtained with oxalic acid dissolved in ethanol.
  • the residual acid chloride was dissolved in 20 ml dichloromethane and added to a solution of 5-aminopentanol (1.8 g, 18 mmol) and triethylamine (4 ml, 28 mmol) in 30 ml dichloromethane at -35oC and the temperature allowed to rise to 0oC in 4 h.
  • the solution was washed with dilute HCl, the organic phase separated, and the solvent removed to yield 2.2 g of a crude oil.
  • This oil was dissolved in 20 ml dichloromethane, triethylamine (4 ml, 28 mmol) and tosylchloride (1.33 g, 7 mmol) were added, and the mixture was stirred at ambient temperature overnight.
  • compositions to be used in the method of the invention.
  • preparation of tablets the following compositions can be made.
  • compositions 1 000 tablets can be made, containing 50 mg and 100 mg of active substance, respectively. If desired, the obtained tablets can be film coated with e.g. hydroxypropyl methyl cellulose in an organic solvent or using water.
  • Tissue preparation The rats are decapitated and the striata dissected out on ice.
  • the tissue is homogenized at 0oC in 20 ml 0.05 M Tris-HCl buffer pH 7.7, using a Branson B30 sonifier.
  • the homogenate is centrifuged at 4oC for 10 minutes at 48000 g, in a Sorvall RC-5B Refrigerated Superspeed Centrifuge. The pellet is resuspended and recentrifuged.
  • the final pellet is resuspended in incubation buffer (0.05 M Tris-HCl pH 7.6 containing 0.1% ascorbic acid, 120 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 and 10 ⁇ M pargylin), to a final concentration of 2.5 mg wet weight/0.5 ml.
  • incubation buffer 0.05 M Tris-HCl pH 7.6 containing 0.1% ascorbic acid, 120 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 and 10 ⁇ M pargylin
  • Receptor binding assay Various concentrations of the test compound, the radioligand (InM H-Raclopride) and the homogenate are incubated for 60 min at room temperature. Non-specific binding is determined by the addition of 1 ⁇ M (+)-Butaclamol. The incubation is terminated by rapid filtration through glass fiber paper (Whatman GF/B) and subsequent washing with cold incubation buffer, using a cell harvester equipment. The radioactivity of the filters is measured in a Packard 2200CA liquid scintillation counter. Data is analyzed by non-linear regression using the LIGAND program, and presented as Ki values.
  • the incubation mixture (2 ml) contained 3 H-8-OH-DPAT (0.25 to 8 nM), 5 mg/ml tissue homogenate in 50 mM Tris-HCl buffer containing 4.0 mM CaCl 2 and 5.7 mM ascorbic acid, pH 7.5.
  • 6 different concentrations of 3 H-8-OH-DPAT were analyzed. Binding experiments were started by the addition of tissue homogenate and followed by incubation at 37oC for ten min.
  • the incubation mixtures were filtered through Whatman GF/B glass filters with a Brandel Cell Harvester (Gaithersburgh, MD, USA).
  • the filters were washed twice with 5 ml ice-cold 50 mM Tris-HCl buffer, pH 7.5, and counted with 5 ml Ultima GoldTM (Packard) in a Beckman LS 3801 scintillation counter. Non-specific binding was measured by the addition of 10 ⁇ M 5-HT to the reaction mixture.
  • the binding data were processed by non-linear least squares computer analysis (Munson and Rodbard, Anal. Biochem. 107, 220-239, (1980). Data were presented as K i values (nM).

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Composé représenté par la formule générale (I) dans laquelle R représente un atome d'hydrogène ou un groupe phényle, m est un entier compris entre 3 et 8, R4 représente un groupe NO2 ou un groupe NR7R8 dans lequel R7 et R8 sont similaires ou différents et chacun représente hydrogène ou alkyle, R5 représente hydrogène, halogène ou CF3, R6 représente halogène ou CF3, W représente un ou des noyaux (x) aromatiques éventuellement substitués, un noyau hétérocyclique, un ou des noyaux carbocyclique ou un groupe méthylène éventuellement substitué, A représente un atome d'hydrogène, un groupe hydroxy, un atome d'halogène, CF3, un groupe alkyle, un groupe alcoxy, un groupe phényle, ou un groupe phenoxy, B représente un atome d'hydrogène ou A et B ensemble constituent un groupe carbonyl, n1 est 0 ou 1 et n2 est 0 ou 1. L'invention décrit également des procédés et des intermédiaires servant à la préparation desdits composés, une préparation pharmaceutique les contenant, ainsi que l'utilisation desdits composés dans le traitement de maladies mentales.
PCT/SE1993/000295 1992-04-09 1993-04-06 Nouvelle piperazine d'aminoalkyle et d'iminoalkyle WO1993021179A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CZ932701A CZ270193A3 (en) 1992-04-09 1993-04-06 Novel amidoalkyl- and imidoalkyl piperazines
EP93909109A EP0594813A1 (fr) 1992-04-09 1993-04-06 Nouvelle piperazine d'aminoalkyle et d'iminoalkyle
JP5518225A JPH06508378A (ja) 1992-04-09 1993-04-06 新規アミドアルキル−およびイミドアルキル−ピペラジン類
AU39643/93A AU665825B2 (en) 1992-04-09 1993-04-06 Novel amidoalkyl- and imidoalkyl-piperazines
SK1389-93A SK138993A3 (en) 1992-04-09 1993-04-06 Amidoalkyl - and imidoalkylpiperazines
NO934426D NO934426D0 (no) 1992-04-09 1993-12-06 Nye amidoalkyl- og imidoalkylpipera-ziner
NO934426A NO180794C (no) 1992-04-09 1993-12-06 Nye amidoalkyl- og imidoalkylpiperaziner samt farmasöytisk preparat inneholdende slike forbindelser
FI935494A FI935494L (fi) 1992-04-09 1993-12-08 Nya amidolakyl- och imidoalkylpiperaziner
BG98281A BG98281A (en) 1992-04-09 1993-12-08 Amidoalkyl- and imidoalkylpiperazines

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9201138A SE9201138D0 (sv) 1992-04-09 1992-04-09 Novel phthalimidoalkylpiperazines
SE9201138-6 1992-04-09
CN93118820A CN1099752A (zh) 1992-04-09 1993-08-31 新型酰氨烷基-和亚氨烷基-哌嗪

Publications (1)

Publication Number Publication Date
WO1993021179A1 true WO1993021179A1 (fr) 1993-10-28

Family

ID=36869961

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1993/000295 WO1993021179A1 (fr) 1992-04-09 1993-04-06 Nouvelle piperazine d'aminoalkyle et d'iminoalkyle

Country Status (14)

Country Link
EP (1) EP0594813A1 (fr)
JP (1) JPH06508378A (fr)
CN (1) CN1099752A (fr)
AU (1) AU665825B2 (fr)
BG (1) BG98281A (fr)
CA (1) CA2109816A1 (fr)
CZ (1) CZ270193A3 (fr)
FI (1) FI935494L (fr)
HU (1) HUT68891A (fr)
NO (2) NO934426D0 (fr)
SE (1) SE9201138D0 (fr)
SI (1) SI9300191A (fr)
SK (1) SK138993A3 (fr)
WO (1) WO1993021179A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995004049A1 (fr) * 1993-07-30 1995-02-09 Recordati S.A., Chemical And Pharmaceutical Company DERIVES DE PIPERAZINE UTILISES COMME ANTAGONISTES DES RECEPTEURS α1A-ADRENERGIQUES
US5395835A (en) * 1994-03-24 1995-03-07 Warner-Lambert Company Naphthalamides as central nervous system agents
WO1995033743A1 (fr) * 1994-06-03 1995-12-14 John Wyeth & Brother Limited Derives de piperazine utilises comme antagonistes de 5ht1a
FR2742149A1 (fr) * 1995-12-11 1997-06-13 Inst Nat Sante Rech Med Nouveaux derives de 2-naphtamides et leurs applications therapeutiques
WO1997034884A1 (fr) * 1996-03-21 1997-09-25 Neurogen Corporation Nouveaux n-aminoalkyl-2-anthracenecarboxamides; nouveaux ligands specifiques de sous-type de recepteur de dopamine
WO1997037983A1 (fr) * 1996-04-05 1997-10-16 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) ANTAGONISTES DU RECEPTEUR α1-ADRENERGIQUE
US6429312B2 (en) 1996-03-21 2002-08-06 Neurogen Corporation N-aminoalkyldibenzothiopencarboxamide receptor subtype specific ligands
WO2003028728A1 (fr) * 2001-09-28 2003-04-10 Richter Gedeon Vegyészeti Gyár Rt. 4-(piperazinyl-1yle substitue en 4)-butylcarboxamides utilises en tant que ligands selectifs du sous-type de la dopamine d3
WO2003029233A1 (fr) * 2001-09-28 2003-04-10 Richter Gedeon Vegyészeti Gyár Rt. Derives de sulfonamide tenant lieu d'agonistes vis-a-vis du recepteur d3 de la dopamine

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004004729A1 (fr) * 2002-07-04 2004-01-15 Schwarz Pharma Ag Heteroarene-carboxamides utilises comme ligands de la dopamine d3 pour traiter des maladies du snc
CN1948298B (zh) * 2006-11-09 2010-09-01 东南大学 一种多巴胺d3受体部分激动剂及其应用

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3398151A (en) * 1966-02-01 1968-08-20 Mead Johnson & Co Azaspirodecanediones and azaspiroundecanediones
FR1537901A (fr) * 1967-07-19 1968-08-30 Bruneau & Cie Lab Dérivés amidés d'acides halogéno et nitro benzoïques et leur préparation
US3465080A (en) * 1968-10-07 1969-09-02 American Cyanamid Co Therapeutic compositions containing morpholinoalkylene - indoles and methods of administering such in the treatment of depression
US3505338A (en) * 1966-11-25 1970-04-07 American Cyanamid Co Thiophenecarbonylalkylene-diamines
GB1198459A (en) * 1966-10-11 1970-07-15 Shulton Inc Substituted 2-Amino and 2-Nitrobenzamides and preparation thereof
US3558777A (en) * 1968-06-21 1971-01-26 Mead Johnson & Co Pharmacologic processes and compositions containing azaspirodecanediones and azaspiroundecanediones
US3940397A (en) * 1974-11-13 1976-02-24 E. R. Squibb & Sons, Inc. 2-[(Substituted-piperazinyl)alkyl]-1H-benz[de]isoquinoline-1,3(2H)-diones
EP0048045A1 (fr) * 1980-09-12 1982-03-24 Duphar International Research B.V Dérivés de phényl-pipérazine ayant une activité antiagressive
US4361565A (en) * 1981-12-28 1982-11-30 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyridines
EP0212551A2 (fr) * 1985-08-21 1987-03-04 Kali-Chemie Pharma GmbH Composés tétraoxo
GB2218988A (en) * 1988-05-24 1989-11-29 American Home Prod Aryl- and heteroaryl piperazinyl carboxamides having central nervous system activity
US4892943A (en) * 1985-10-16 1990-01-09 American Home Products Corporation Fused bicyclic imides with psychotropic activity
US4939137A (en) * 1989-06-28 1990-07-03 Ortho Pharmaceutical Corporation Ring-fused thienopyrimidinedione derivatives
EP0376633A2 (fr) * 1988-12-28 1990-07-04 Suntory Limited Dérivés de benzoxazépine
WO1991009594A1 (fr) * 1989-12-28 1991-07-11 Virginia Commonwealth University Ligands de recepteur sigma et leur emploi
US5143923A (en) * 1991-04-29 1992-09-01 Hoechst-Roussel Pharmaceuticals Inc. Benzoisothiazole- and benziosoxazole-3-carboxamides
EP0526434A1 (fr) * 1991-07-30 1993-02-03 BOEHRINGER INGELHEIM ITALIA S.p.A. Dérivés de benzimidazolone comme antagonistes de 5-HT1A et 5-HT2

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS504650B2 (fr) * 1971-09-03 1975-02-22

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3398151A (en) * 1966-02-01 1968-08-20 Mead Johnson & Co Azaspirodecanediones and azaspiroundecanediones
GB1198459A (en) * 1966-10-11 1970-07-15 Shulton Inc Substituted 2-Amino and 2-Nitrobenzamides and preparation thereof
US3505338A (en) * 1966-11-25 1970-04-07 American Cyanamid Co Thiophenecarbonylalkylene-diamines
FR1537901A (fr) * 1967-07-19 1968-08-30 Bruneau & Cie Lab Dérivés amidés d'acides halogéno et nitro benzoïques et leur préparation
FR93884E (fr) * 1967-07-19 1969-05-30 Lab Bruneau Et Cie Dérivés amidés d'acides halogéno et nitro benzoiques et leur préparation.
US3558777A (en) * 1968-06-21 1971-01-26 Mead Johnson & Co Pharmacologic processes and compositions containing azaspirodecanediones and azaspiroundecanediones
US3465080A (en) * 1968-10-07 1969-09-02 American Cyanamid Co Therapeutic compositions containing morpholinoalkylene - indoles and methods of administering such in the treatment of depression
US3940397A (en) * 1974-11-13 1976-02-24 E. R. Squibb & Sons, Inc. 2-[(Substituted-piperazinyl)alkyl]-1H-benz[de]isoquinoline-1,3(2H)-diones
EP0048045A1 (fr) * 1980-09-12 1982-03-24 Duphar International Research B.V Dérivés de phényl-pipérazine ayant une activité antiagressive
US4361565A (en) * 1981-12-28 1982-11-30 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyridines
EP0212551A2 (fr) * 1985-08-21 1987-03-04 Kali-Chemie Pharma GmbH Composés tétraoxo
US4892943A (en) * 1985-10-16 1990-01-09 American Home Products Corporation Fused bicyclic imides with psychotropic activity
GB2218988A (en) * 1988-05-24 1989-11-29 American Home Prod Aryl- and heteroaryl piperazinyl carboxamides having central nervous system activity
EP0376633A2 (fr) * 1988-12-28 1990-07-04 Suntory Limited Dérivés de benzoxazépine
US4939137A (en) * 1989-06-28 1990-07-03 Ortho Pharmaceutical Corporation Ring-fused thienopyrimidinedione derivatives
WO1991009594A1 (fr) * 1989-12-28 1991-07-11 Virginia Commonwealth University Ligands de recepteur sigma et leur emploi
US5143923A (en) * 1991-04-29 1992-09-01 Hoechst-Roussel Pharmaceuticals Inc. Benzoisothiazole- and benziosoxazole-3-carboxamides
US5143923B1 (en) * 1991-04-29 1993-11-02 Hoechst-Roussel Pharmaceuticals Incorporated Benzoisothiazole-and benzisoxazole-3-carboxamides
EP0526434A1 (fr) * 1991-07-30 1993-02-03 BOEHRINGER INGELHEIM ITALIA S.p.A. Dérivés de benzimidazolone comme antagonistes de 5-HT1A et 5-HT2

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Volume 110, No. 5, 30 January 1989 (30.01.89), (Columbus, Ohio, USA), GIARDINA DARIO et al., "Structure-activity relationships in prazosin-related compounds. Effect of replacing a piperazine ring with an alkanediamine moiety on x1-adrenoreceptor blocking activity", page 540, The Abstract *
CHEMICAL ABSTRACTS, Volume 80, No. 1, 7 January 1974 (07.01.74), (Columbus, Ohio, USA), page 288, The Abstract No. 37015m; & FR,A,2167355, (CARRON, CLAUDE L.C. et al.) 28 Sept 1973 (28.09.73), see reg.no. 50845-96-0. *
CHEMICAL ABSTRACTS, Volume 94, No. 25, 22 June 1981 (22.06.81), (Columbus, Ohio, USA), KORMENDY, KAROLY et al., "Aminophthalazinone derivatives. VI. Synthesis of 4-(hydroxyalkylamino)1-(2H)-benzo(g)phthala zinones", page 594, The Abstract No. 208787k, Acta Chim. Acad. Sci. Hung. 1980, 105 (3), 175-188, see reg.no. 77766-48-4. *
J. Indian Chem. Soc., Volume LVI, October 1979, SAMANT et al., "Synthesis and Pharmacology of N-(N4-Aryl-N1-Piperaziny lalkyl)Phthalimides: CNS Depressants", page 1002 - page 1005, see page 1004. *
J. Med. Chem., Volume 31, October 1988, RICHARD A. GLENNON et al., "Arylpiperazine Derivatives as High-Affinity 5-HT1A Serotonin Ligands", page 1968 - page 1971, see especially compounds 15-17 and 23-24. *
J. Med. Chem., Volume 32, August 1989, RICHARD A. GLENNON et al., "N-(Phthalimidoalkyl)Derivatives of Serotonergic Agents: A Common Interaction at 5-HT1A Serotonin Binding Sites?", page 1921 - page 1926, see table II. *
J. Med. Chem., Volume 34, August 1991, REVATHI K. RAGHUPATHI et al., "Analogues of the 5-HT 1A Serotonin Antagonist 1(2-Methoxy-phenyl)-4-/4-(2-phthalimido)but yl/pipe razine with Reduced alfal-Adrenergic Affinity", page 2633 - page 2638, see especially compounds 1c, 1f and 2a-2c. *
Journal of Pharmaceutical Sciences, Volume 77, No. 10, October 1988, KHALID A. AL-RASHOOD et al., "Antipsychotic Properties of New N-(4-Substituted-1-Piperazinylethyl)- and N-(4-Substituted-1-Piperidinylethyl)-Phthal imides", page 898 - page 901, see table II. *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995004049A1 (fr) * 1993-07-30 1995-02-09 Recordati S.A., Chemical And Pharmaceutical Company DERIVES DE PIPERAZINE UTILISES COMME ANTAGONISTES DES RECEPTEURS α1A-ADRENERGIQUES
US5395835A (en) * 1994-03-24 1995-03-07 Warner-Lambert Company Naphthalamides as central nervous system agents
WO1995025727A1 (fr) * 1994-03-24 1995-09-28 Warner-Lambert Company Naphtylamides comme agents actifs sur le systeme nerveux central
US5723464A (en) * 1994-06-03 1998-03-03 American Home Products Corporation Piperazine derivatives
WO1995033743A1 (fr) * 1994-06-03 1995-12-14 John Wyeth & Brother Limited Derives de piperazine utilises comme antagonistes de 5ht1a
CN1093122C (zh) * 1994-06-03 2002-10-23 约翰韦恩兄弟有限公司 作为5－ht1a拮抗剂的哌嗪衍生物
CN1048985C (zh) * 1994-06-03 2000-02-02 约翰韦恩兄弟有限公司 作为5－ht1a拮抗剂的哌嗪衍生物
FR2742149A1 (fr) * 1995-12-11 1997-06-13 Inst Nat Sante Rech Med Nouveaux derives de 2-naphtamides et leurs applications therapeutiques
US5872119A (en) * 1995-12-11 1999-02-16 Institut National De La Sante et De La Recherche Medicale--INSERM 2-Naphthamide derivatives and their therapeutic applications
EP0779284A1 (fr) * 1995-12-11 1997-06-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nouveaux dérivés de 2-naphthamides et leurs applications thérapeutiques comme agonistes des récepteurs D3
WO1997034884A1 (fr) * 1996-03-21 1997-09-25 Neurogen Corporation Nouveaux n-aminoalkyl-2-anthracenecarboxamides; nouveaux ligands specifiques de sous-type de recepteur de dopamine
US6239179B1 (en) 1996-03-21 2001-05-29 Neurogen Corporation N-aminoalkyl-2-anthracenecarboxamides; new dopamine receptor subtype specific ligands
US6429312B2 (en) 1996-03-21 2002-08-06 Neurogen Corporation N-aminoalkyldibenzothiopencarboxamide receptor subtype specific ligands
WO1997037983A1 (fr) * 1996-04-05 1997-10-16 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) ANTAGONISTES DU RECEPTEUR α1-ADRENERGIQUE
WO2003028728A1 (fr) * 2001-09-28 2003-04-10 Richter Gedeon Vegyészeti Gyár Rt. 4-(piperazinyl-1yle substitue en 4)-butylcarboxamides utilises en tant que ligands selectifs du sous-type de la dopamine d3
WO2003029233A1 (fr) * 2001-09-28 2003-04-10 Richter Gedeon Vegyészeti Gyár Rt. Derives de sulfonamide tenant lieu d'agonistes vis-a-vis du recepteur d3 de la dopamine
US7473692B2 (en) 2001-09-28 2009-01-06 Richter Gedeon Vegyeszeti Gyar Rt. Sulfonamide derivatives as D3-receptor ligands

Also Published As

Publication number Publication date
BG98281A (en) 1994-09-30
NO180794B (no) 1997-03-17
CA2109816A1 (fr) 1993-10-28
NO934426D0 (no) 1993-12-06
JPH06508378A (ja) 1994-09-22
SI9300191A (sl) 1993-12-31
SK138993A3 (en) 1994-11-09
CZ270193A3 (en) 1994-08-17
CN1099752A (zh) 1995-03-08
AU3964393A (en) 1993-11-18
SE9201138D0 (sv) 1992-04-09
AU665825B2 (en) 1996-01-18
NO180794C (no) 1997-06-25
NO934426L (no) 1993-12-06
HUT68891A (en) 1995-08-28
FI935494A0 (fi) 1993-12-08
FI935494L (fi) 1993-12-08
EP0594813A1 (fr) 1994-05-04

Similar Documents

Publication Publication Date Title
EP0376607B1 (fr) Dérivés pipérazinoyles
US5159083A (en) Certain aminomethyl phenylimidazole derivatives; a class of dopamine receptor subtype specific ligands
US6521623B1 (en) N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
US5834493A (en) Indole derivatives as 5-HT1A and/or 5-HT2 ligands
FR2655988A1 (fr) Nouveaux derives de la napht-1-yl piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
SK281457B6 (sk) 3-[4-(4-(4-kyánfenyl)-1-piperazinyl)butyl]-5-kyánindol, spôsob jeho prípravy, jeho použitie a farmaceutický prostriedok, ktorý ho obsahuje
US20030083336A1 (en) Phenylpiperazinyl derivatives
SK6492001A3 (en) New piperazine and piperidine compounds
US5972937A (en) Heterocyclic compounds possessing 5HT2C receptor antagonist activity
SE465928B (sv) 1,2,4-triazolonfoereningar med antidepressiv aktivitet, foerfarande foer framstaellning av dessa och en farmaceutisk komposition
WO1993021179A1 (fr) Nouvelle piperazine d'aminoalkyle et d'iminoalkyle
EP1246817B1 (fr) Derives de 4-phenyle-1-piperazinyle, -piperidinyle et -tetrahydropyridyle
AU683700B2 (en) Phenylindole compounds
US5030639A (en) N-substituted-5,6-dimethoxy-1,2-benzisoxazole-3-propanamine and related compounds as analgesic and hypotensive agents
JP5062938B2 (ja) セロトニン受容体及びドーパミン受容体にアフィニティーを有する新規ｎ，ｎ’−二置換ベンゾイミダゾロン誘導体
JP2008509962A (ja) ５−ｈｔ７受容体アンタゴニスト
US5472966A (en) Antidepressant heteroarylaminoalkyl derivatives of naphthyl-monazines
JP2008509961A (ja) ５−ｈｔ７受容体アンタゴニスト
EP0543584B1 (fr) Benzo(b)thiophène-2-carboxamides pour le traitement de maladies du système nerveux central
DE60000790T2 (de) [(2-substituierte-5-[3-thienyl)-benzyl]-[2-([2-isopropoxy-5-fluoro]-phenoxy)-ethyl]-amine, verfahren zu ihrer herstellung und ihre verwendung als medikamente
US5420130A (en) 2-aminopyrazine-5-carboxamide derivatives, their preparation and their application in therapeutics
US20060247256A1 (en) Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition
CA2587936A1 (fr) Indoles de tetrahydropyridine-4-yle comportant une combinaison de sites a affinite avec des recepteurs de dopamine d2 et inhibant la reabsorption de la serotonine
CZ284463B6 (cs) N-Substituované azabicykloheptanové deriváty
KR20010072407A (ko) Ｎ-치환 아자비시클로헵탄 유도체, 그의 제조 및 용도

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR CA CZ FI HU JP KP KR KZ LK MG MN MW NO NZ PL RO RU SD SK UA VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 251786

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1993909109

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2109816

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 93-01633

Country of ref document: RO

WWE Wipo information: entry into national phase

Ref document number: 935494

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: PV1993-2701

Country of ref document: CZ

Ref document number: 138993

Country of ref document: SK

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1993909109

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1993-2701

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: PV1993-2701

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1993909109

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载